[1] Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect,2011,17:107-115.
[2] Rao H,Wei L,Lopez-Talavera JC,et al. Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection.J Gastroenterol Hepatol,2014,29（3）:545-553.
[3] Messina JP,Humphreys I,Flaxman A,et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology,2015,61:77-87.
[4] Tapper EB,Afdhal NH. Is 3 the new 1:perspectives on virology, natural history and treatment for hepatitis C genotype 3. J Viral Hepat,2013,20:669-677.
[5] 中华医学会肝病学分会,中华医学会感染病学分会. 丙型肝炎防治指南（2015更新版）. 中华肝脏病杂志,2015,23（12）: 906-923.
[6] European Association for Study of Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol,2015,63（1）:199-236.
[7] Omata M,Kanda T,Yu ML,et al. APASL consensus statements and management algorithms for hepatitis C virus infection.Hepatol Int,2012,6（2）：409-435.
[8] WHO. Guidelines for the screening, care and treatment of persons with hepatitis C infection.http://www.who.Int/hepatitis/publications/hepatitis-c-guidelines/en/.
[9] Lawitz E, Mangia A,Wyles D,et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med,2013,368:1878-1887.
[10] Jacobson IM,Gordon SC,Kowdley KV,et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med,2013,368:1867-1877.
[11] Zeuzem S,Dusheiko GM,Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. Gastroenterology,2014,370:1993-2001.
[12] Esteban R,Nyberg L,Lalezari J,et al. Successful retreatment with sofosbuvir-containing regimens for HCV genotype 2 or 3infected patients who failed prior sofosbuvir plus ribavirin therapy. J Hepatol,2014,60:S4-S5.
[13] Alqahtani S,Zeuzem S,Manns M,et al. Safety and effectiveness of sofosbuvir-based regimens for the treatment of hepatitis C genotype 3 and 4 infections:Interim analysis of a prospective, observational study. J Hepatol,2015,62:S652-S653.
[14] Kowdley K,Bacon B,Dieterich D,et al. Efficacy evaluation of 24 week SOF+RBV in a heterogeneous,real-world population of genotype 3 HCV patients:Data from the TRIO network. J Hepatol,2015,62:S665-S666.
[15] Lawitz E,Lalezari JP,Hassanein T,et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for noncirrhotic,treatment-naive patients with genotypes 1,2, and 3 hepatitis C infection:a randomised,double-blind,phase 2 trial. Lancet Infect Dis,2013,13:401-408.
[16] Lawitz E,Poordad F,Brainard DM,et al. Sofosbuvir in combination with PegIFN and ribavirin for 12 weeks provides high SVR rates in HCV-infected genotype 2 or 3 treatment-experienced patients with and without compensated cirrhosis:results from the LONESTAR-2 study. Hepatology, 2013,58:1380A
[17] Foster GR,Pianko S,Brown A,et al. Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection. Gastroenterology,2015,149:1462-1670.
[18] Sulkowski MS,Gardiner DF,Rodriguez-Torres M,et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med,2014,370:211-221.
[19] Nelson DR,Cooper JN,Lalezari JP,et al. Alloral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection:ALLY-3 phase 3 study. Hepatology,2015,61:1127-1135.
[20] Foster GR,McLaughlan J,Irving W,et al. Treatment of decompensated HCV cirrhosis in patients with diverse genotypes:12 weeks of sofosbuvir and NS5A inhibitors with/without ribavirin is effective in HCV genotypes 1 and 3. J Hepatol,2015,62:S190-S191.
[21] Poordad F,Schiff ER,Vierling JM,et al. Daclatasvir,sofosbuvir,and ribavirin combination for HCV patients with advanced cirrhosis or post-transplant recurrence:ALLY-1 phase 3 study. J Hepatol,2015,62:S261-S262.
[22] Gane EJ,Hyland RH,An D,et al. Efficacy of ledipasvir and sofosbuvir,with or without ribavirin,for 12 weeks in patients with HCV genotype 3 or 6 infection. Gastroenterology,2015,1449:1454.
[23] Bourlière M,Bronowicki JP,de Ledinghen V,et al. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy:a randomised,double-blind, phase 2 trial （SIRIUS）. Lancet Infect Dis,2015,15:397-404.
[24] Hezode C,De Ledinghen V,Fonatine H, et al. Daclatasvir plus sofosbuvir with or without ribavirin in patients with HCV genotype 3 infection:Interim analysis of a French multicenter compassionate use program. J Hepatol,2015,62:S265-S266.
[25] Larrat S,Vallet S,David-Tchouda S,et a1. Naturally occurring resistance-associated variants of hepatitis C virus protease inhibitors in poor responders to pegylated interferon-ribavirin.J Clin Microbiol,2015,53（7）：2195-2202.
[26] Shoeb D,Dearden J,Weatherall A,et al. Extended duration therapy with pegylated interferon and ribavirin for patients with genotype 3 hepatitis C and advanced fibrosis: final results from the STEPS trial. J Hepatol,2014,60:699-705.
[27] Foster GR,Afdhal N,Roberts SK,et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med,2015,373（27）:2608-2617. |
